Methods Aerobika* (Trudell Medical International, Canada) and AirPhysio (AirPhysio, Australia) OPEP devices (n=3) were assessed at steady expiratory flows of 10–30L/min using a flow generator (Resmed ...

ResMed Inc (NYSE:RMD) continues to innovate with the launch of new products like NightOwl and VPAP Tx, enhancing its digital health ecosystem and expanding its market reach. ResMed Inc (NYSE ...

VPAP Tx is purpose-built to support everything that a sleep physician needs in the sleep lab, including titration, evaluation and setup across every therapy mode that ResMed offers, including CPAP ...

The launch of new diagnostic and therapy solutions, such as NightOwl and VPAP Tx, marked a strategic ... trade and tariffs but confirmed that ResMed's medical devices are exempt, mitigating ...

ResMed Inc (NYSE:RMD) continues to innovate with the launch of new products like NightOwl and VPAP Tx, enhancing its digital health ecosystem and expanding its market reach. ResMed Inc (NYSE:RMD) ...

Brett Fishbin; Analyst; KeyBanc Capital Markets Inc. Greetings, and welcome to the Q3 fiscal year 2025 ResMed earnings conference call. My name is Kevin, and I'll be your operator for today's call.

SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) — Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the ...

ResMed has appointed Salli Schwartz as the new Chief Investor Relations Officer, effective April 21, 2025. Schwartz brings over two decades of experience from roles in finance at health tech and ...

SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the ...

ResMed is taking a “smart devices” and Big Data approach to further entrench itself as one of the two leading players in the global obstructive sleep apnea, or OSA, market. With cloud ...

Brett Fishbin; Analyst; KeyBanc Capital Markets Inc. Greetings, and welcome to the Q3 fiscal year 2025 ResMed earnings conference call. My name is Kevin, and I'll be your operator for today's call.